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Abstract. The blocking effect of the NH2-terminal deca- 
peptide of a-smooth muscle (SM) actin AcEEED- 
STALVC on the binding of the specific monoclonal an- 
tibody anti--aSM-1 (Skalli, O., P. Ropraz, A. Trzeviak, 
G. Benzonana, D. Gillessen, and G. Gabbiani. 1986. J. 
Cell Biol. 103:2787-2796)  was compared with that of 
synthetic peptides modified by changing the acetyl 
group or by substituting an amino acid in positions i  to 
5. Using immunofluorescence and immunoblotting 
techniques, anti-aSM-1 binding was abolished by the 
native peptide and by peptides with a substitution in 
position 5, indicating that AcEEED is the epitope for 
anti-aSM-1. Incubation of anti-aSM-1 (or of its Fab 
fragment) with arterial SM actin increased polymeriza- 
tion in physiological salt conditions; the antibody bind- 
ing did not hinder the incorporation of the actin anti- 
body complex into the filaments. This action was not 
exerted on skeletal muscle actin. 
After microinjection of the et-SM actin NH2-terminal 
decapeptide or of the epitopic peptide into cultured 
aortic smooth muscle cells, double immunofluores- 
cence for ct-SM actin and total actin showed a selective 
disappearance of a-SM actin staining, detectable at 
~30 min. When a control peptide (e.g. a-skeletal [SKI 
actin NH2-terminal peptide) was microinjected, this 
was not seen. This effect is compatible with the possibil- 
ity that the epitopic peptide traps a protein involved in 
a-SM actin polymerization  during the dynamic  filament 
turnover in stress fibers. Whatever the mechanism, this 
is the first evidence that the NH2 terminus of an actin 
isoform plays a role in the regulation of polymerization 
in vitro and in vivo. 
CTIN isoforms are characterized by slightly different 
sequences particularly at their NH2-terminal ends 
(Vandekerckhove and Weber, 1978; Vandekerck- 
hove and Weber,  1979). They are  produced by distinct 
genes (Ponte et al.,  1983) and the sequences of each of 
them  are  perfectly conserved  in  higher vertebrates.  In 
adult animals the two cytoplasmic isoforms (13 and ~/) are 
present in all cells, albeit in variable proportions, and the 
four muscular isoforms are characteristically expressed re- 
spectively in skeletal  (a-skeletal)  and cardiac  (a-cardiac) 
muscles or in different smooth muscles (SM) 1, et-SM actin 
being abundant in vascular SM and ~/-SM actin being abun- 
dant in parenchymal SM, especially in the gastro-intestinal 
tract (Vandekerckhove  and Weber, 1981; SkaUi et al., 1987). 
Another feature of actin isoforms is their sequential expres- 
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1. Abbreviations used in this paper. SK, skeletal; SM, smooth muscle. 
sion during development, particularly studied in skeletal 
and cardiac muscles (Ruzicka and Schwartz, 1988; Wood- 
cock-Mitchell et al., 1988). a-SM actin has also been shown 
to appear ex novo in stress fibers of fibroblastic  cells dur- 
ing pathological situations involving contractile phenom- 
ena such as wound healing and fibrocontractive diseases 
(Janmey and Chaponnier, 1995). Despite the phylogenetic 
conservation and the highly coordinated expression pattern, 
there is no definite evidence  of actin isoform differential 
functions. On the contrary, it has been shown that skeletal 
actin microinjected in cultured fibroblastic cells incorporates 
readily into stress fibers (McKenna et al., 1985). 
Due to the high homology among actin isoforms it has 
been difficult to raise specific antibodies. A few years ago an 
antibody selectively recognizing a-SM actin was produced 
(Skalli et al., 1986b). We report here that the epitope of this 
antibody is the NH2-terminal  sequence AcEEED. More- 
over we show that the interaction of the antibody or its Fab 
fragment with aortic SM actin lowers the critical monomer 
concentration for polymerization and that microinjection 
of the epitopic peptide in cultured SM cells induces the se- 
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gesting  that  the  epitope  sequence  unique  to a-SM  actin 
plays a role in polymerization. 
Materials and Methods 
Peptides 
Peptides with the NH2-terrninal sequences of the six mammalian actin iso- 
forms, extending until Cys-10, and a-SM related peptides with substitu- 
tion at the blocking group or in positions 1, 2, 3, 4, or 5 were synthesized 
with a synthesizer (431A; Applied Biosystems Inc., Foster City, CA) on 
p-hydroxymethylphenoxymethyl copolystyrene 1%  divinylbenzene resin 
using the Fmoc chemistry procedure and following the manufacturer's in- 
structions. The peptides were acetylated or butyrylated while being at- 
tached to the resin in the side-chain protected form with acetic or butyric 
anhydride after removal of the last fluorenylmethyloxycarbonyl  group. 
After cleaving the protective groups and the peptide-resin conjugates, 
the peptides were precipitated with t-methyl-butylether and collected by 
centrifugation at 2,000 g. The residue was further dried for 2 h in a Speed- 
vac  concentrator  (Savant  Instruments, Farmingdale,  NY),  then  redis- 
solved in H20 and adjusted to pH 8.0 with 4 M NaOH. The peptides were 
desalted over a G-25 column (2 × 25 cm) in H20. The eluates were moni- 
tored by UV absorbance at 254 nm. 
Peptides were coupled to BSA essentially as described by Green et al. 
(1982) and Gimona et al. (1994). 25 mg of BSA dissolved in 2 ml of 10 mM 
phosphate buffer, pH 7.2, were allowed to react with 4.2 mg of maleimido- 
benzoyl-N-hydroxysuccinimide  dissolved in 50 ixl dimethyl formamide un- 
der argon atmosphere. Excess reagent was then removed by gel-filtration 
in 50 mM phosphate buffer at pH 6.0 and the protein-containing fraction 
collected and adjusted with NaOH to pH 7.0.  Each peptide (2 mg) was 
consecutively coupled  for 3  h  to  700-~1  aliquots of the MBS-activated 
BSA (~1/20 of the amount collected after gel filtration). Aliquots were 
mixed with sample buffer for SDS-gel electrophoresis and Western blot- 
ting. The peptides AcEEED-NH2 and EEED-NH~ were purchased from 
Research Genetics (Huntsville, AL). 
Protein Purification 
Preparation of acetone powder of bovine aorta tunica media and purifica- 
tion of SM actin were carried out according to Strzeleeka-Golaszewska et 
al. (1985).  Actin from rabbit skeletal muscle acetone powder was purified 
by the method of Spudich and Watt (1971). 
Anti-aSM-I IgG2a (Skalli et al., 1986b) was purified from hybridoma 
supernatants by  affinity  chromatography on  protein  A-Sepharose  4B 
(Pharmacia, Uppsala, Sweden) and dialyzed against G-actin buffer (buffer 
G: 2  mM Tris-HC1, 0.2 mM ATP, 0.5 mM 2-mercaptoethanol, 0.2 mM 
CaCl2, final pH 7.8; Spudich and Watt, 1971) for sedimentation assays. 
A  two-step method for the preparation of the monovalent Fab frag- 
ment from purified anti-aSM-1 was used because of the peculiar sensitiv- 
ity to papain digestion of the IgG2a molecule (Parham, 1986). The F(ab')2 
was obtained by limited proteolytic digestion with pepsin at pH 4.2 (Par- 
ham, 1986).  The intact immunoglobulin and the Fc portion were retained 
on a  protein A-Sepharose column (Pharmacia). The flow through frac- 
tion, containing the F(ab')2 portion, was dialyzed against 0.1 M Tris-HCl, 
pH 7.5, and reduced with a freshly made cysteine solution (10 mM final) at 
pH 7.5 for 2 h at 37°C to obtain the monovalent Fab fragment. Alkylatiou 
was performed using 0.15 M final iodoacetamide for 30 min at room tem- 
perature. 
SDS-PA  GE and Immunoblots 
Electrophoresis of proteins was performed on 5-20% gradient SDS-poly- 
acrylamide gels according to Laemmli (1970). Immunoblots were essen- 
tially performed according to Towbin et al. (1979)  with minor modifica- 
tions (Chaponnier et al., 1990).  Anti-aSM-1 hybridoma supernatant was 
diluted  1:500  and  peroxidase-conjugated  affinity-purified  goat-anti- 
mouse  IgG  plus  IgM  (Jackson  ImmunoReseareh Laboratories,  West 
Grove, PA) 1:10,000.  The membrane bound peroxidase-labeled antibod- 
ies were detected using the ECL Western blotting system (Amersham, 
Rahn AG, ZUrich, Switzerland), according to the instructions of the man- 
ufacturer. For quantification, Coomassie blue stained gels and films were 
scanned with a computerized laser beam densitometer (Genofit, Geneva, 
Switzerland). 
Sedimentation Assays 
Stock solutions of 10 ~M G-actin (aortic smooth muscle or skeletal muscle 
actin), 5 ixM anti-aSM-1 IgG, 10 p~M anti-aSM-1 Fab, buffer G, and Hisalt 
buffer (300 mM KC1, 6 mM MgC12 in buffer G) were used for polymeriza- 
tion assays. All proteins were dialyzed against buffer G. G-actin (50 txl) 
was mixed with: (a) buffer G  (100 ~l), (b) buffer G  (50 ~l)  and Hisalt 
buffer (50 txl), (c) anti-aSM-1 IgG or Fab (50 Ixl) and Hisalt buffer (50 Ixl), 
(4) anti-aSM-1 IgG or Fab (50 p.1) and buffer G (50 i~l) and allowed to po- 
lymerize at  room temperature  for 30 rain.  F-actin and bound proteins 
were sedimented at 30 psi for 60 rain in a Beckman Airfuge using an A-100 
fixed-angle rotor (Beckman Instrument Co., Fullerton, CA). Equivalent 
amounts of the pellets and supernatants were analyzed by SDS-PAGE 
(Chaponnier et al., 1985). 
Control experiments were performed to rule out nonspecific interac- 
tions. An unrelated IgG was used instead of anti-ctSM-1; moreover excess 
peptides (decapeptides P1  and P2, tetrapeptides AcEEED  and EEED) 
were mixed for 10 min at room temperature with anti-aSM-1 before the 
addition of actin for the 30 rain polymerization time before centrifugation 
(see above). 
Pyrene-Actin Assays 
The rate and extent of actin polymerization were measured using pyrene- 
labeled a-SM and a-skeletal (SK) actins. Pyrene-labeled actin monomers 
undergo a  characteristic 20-fold increase in fluorescence intensity when 
incorporated into filaments (Kouyama and Mihashi, 1981).  The rate and 
extent of the fluorescence increase are directly related to the rate and ex- 
tent of actin polymerization, a-SM actin was labeled by the method of 
Kouyama and Mihashi (1981).  To measure the effects of anti-aSM-1 on 
polymerization,  a  concentration of labeled a-SM actin  (a-SM  PIA)  or 
a-SK actin (a-SK PIA) below the critical concentration required for spon- 
taneous polymerization was mixed with various concentrations of unla- 
beled a-SM or a-SK actin and anti-aSM-1. The rate of polymerization 
was determined by continuously monitoring fluorescence emission at 386 
nm with excitation at 365 nm using a fluorimeter (LSS0-B; Perkin-Elmer 
Corp., Norwalk, CT) after addition of 2 mM MgC12 and 100 mM KCI to 
initiate  polymerization.  The  extent  of polymerization  was  determined 
from the steady state fluorescence measured 12 h  after polymerization 
was started. 
Electron Microscopy 
The polymerization conditions for negative staining at the electron micro- 
scopic level were identical to those described above. Actin (final concen- 
tration 3.3 IxM) was allowed to polymerize with and without anti-aSM-1 
IgG or Fab for 30 rain. Samples were applied to carbon coated grids and 
stained with 1% uranyl acetate (Chaponnier et aI., 1985). 
Microinjection and Fluorescence  Microscopy 
SM cells were isolated from the thoracic aorta of 6-wk-old Wistar rats by 
enzymatic digestion (Skalli et al., 1986a) and used at passage 2-5. 10,000 
cells were plated on 60-mm diam Petri dishes (Nunc; Gibco, Basel, Swit- 
zerland) and grown for 5-6 d in DME (Gibco), supplemented with 10% 
fetal calf serum. Microinjections were performed at room temperature by 
means of a Leitz micromanipulator (Leitz, Wetzlar, Germany), equipped 
with a  vacuum and pressure device (Injectmatic, Geneva, Switzerland), 
using an inverted microscope equipped with phase contrast optics (Carl 
Zeiss, Inc.,  Oberkochen,  Germany)  as  described  earlier  (Skalli  et  al., 
1990).  Cells were microinjected with the unlabeled or biotinylated a-SM 
actin NH2-terminal decapeptide (AcEEEDSTALVC), or with the epitopic 
tetrapeptide (AcEEED) at 1 mg/ml in PBS; PBS alone or an a-SM actiu 
related terminal peptide inactive in our tests (generally P2 [Table I]), were 
used as controls. After returning to the incubator for up to 5 h, cells were 
washed twice with PBS containing 0.5 mM CaCl2 and 3 mM MgC12, fixed 
with 3% paraformaldehyde for 10 min and permeabilized with 0.1% Tri- 
ton X-100 in PBS for 1 min. Double immunofluorescence stainings were 
performed for a-SM actin and total actin using anti-aSM-1 (Skalli et al., 
1986b)  and a  rabbit polyclonal general anti-actin antibody, respectively 
(Skalli et al., 1990),  followed by TRITC- or FITC-conjugated goat anti- 
mouse IgG (Jackson) and FITC-conjugated goat anti-rabbit IgG (Jack- 
son),  Rhodamine-labeled  phalloidin  (Molecular  Probes,  Inc.,  Eugene, 
OR) was also used to detect total polymerized actin instead of anti-actin 
general antibody. The biotinylated peptide was detected by FITC-strepta- 
vidin (F 422;  Dako A/S, Glostrup, Denmark). After several rinsings in 
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Related Synthetic Peptides on Anti-aSM-1  Binding* 
P1  Ac. EEEDSTALVC.OH  a-smooth  Yes 
P2  Ac. DEDETTALVC.OH  a-skeletal  No 
P3  Ac. DDEETTALVC.OH  a-cardiac  No 
P4  Ac. EEETTALVC.OH  ~/-smooth  No 
P5  Ac. EEEIAALVC.OH  ~-cytoplasmic  No 
P6  Ac. DDDIAALVC.OH  13-cytoplasmic  No 
P7  NH2.EEEDSTALVC.OH  No 
P8  But.EEEDSTALVC.OH  No 
P9  Ac. _EEDSTALVC.OH  No 
P10  Ac. DEEDSTALVC.OH  No 
P11  Ac. AEEDSTALVC.OH  Partial 
P12  Ac. EDEDSTALVC.OH  No 
P13  Ac. EAEDSTALVC.OH  No 
PI4  Ac. EEDDSTALVC.OH  No 
P15  Ac. EEADSTALVC.OH  No 
P16  Ac. EEEESTALVC.OH  Partial 
P17  Ac. EEEGSTALVC.OH  No 
P18  Ac. EEEDATALVC.OH  Yes 
P19  Ac. EEEDLTALVC.OH  Yes 
*The amino acids in bold characters are those differing from the sequence of the 
c~-SM actin NH2-terminal  peptide (P1). 
PBS, the preparations were mounted in buffered polyvinyl alcohol (Len- 
nett, 1978). Photographs were taken with a Zeiss Axiophot photomicro- 
scope (Carl Zeiss) equipped for epiillumination and specific filters for flu- 
orescein and rhodamine, using a plan apochromatic 63x/1.4 objective and 
Kodak T-MAX 400 film (Eastman Kodak, Rochester, NY). 
Results 
The Ac-EEED Sequence Constitutes the Epitope 
Recognized by Anti-a-SM-1 
The  monoclonal  antibody anti-aSM-1  was originally  ob- 
tained after sensitization with the NH2-terminal decapep- 
tide of e~-SM actin (Skalli et al., 1986b). The corresponding 
free peptide (Table I, peptide P1) specifically blocked spe- 
cific  a-SM  actin  detection  during  immunofluorescence 
staining of different mammalian tissues. A  similar inhibi- 
tory effect was also observed when a rat aorta protein total 
extract was screened by immunoblotting in the presence of 
the  decapeptide  (Fig.  1).  Peptides  corresponding  to  the 
NH2-terminal sequences of other vertebrate actins (Table 
I, peptides P2-P6) were inactive when used as inhibitors in 
both immunofluorescence and Western blotting (Fig. 1). 
To obtain more details on the  amino acid residues in- 
volved in the interaction with the  antibody, we first syn- 
thesized  a  number of variants of P1, in which either the 
acetyl group was deleted or substituted by a  more bulky 
butyryl group  (Table  I, P7  and P8).  Both peptides were 
unable  to  compete  with  et-SM  actin  for  the  antibody, 
stressing  the  importance  of  the  presence  of  the  acetyl 
group at the  NH2-terminal end.  The  remaining peptides 
were designed by substituting  at positions  1-4 the  acidic 
residues by either the other acidic side chain (exchanging 
Asp for Glu and vice-versa) or a small neutral residue (ei- 
ther Ala or Gly). At position 5 the serine residue was re- 
placed by either a small (Ala) or bulky (Leu) hydrophobic 
residue (Table I, P10-P19). The binding of anti-aSM-1 to 
et-SM actin was never blocked when substitutions, includ- 
ing conserved substitutions (i.e., Glu by Asp), happened in 
position 2  or 3.  Interestingly, exchanging Glu by the un- 
charged Ala in position 1 resulted in a partial blocking of 
anti-aSM-1 binding while substituting Glu by Asp had no 
effect. In position 4, however, only the conserved substitu- 
tion Asp for Glu resulted in a partial effect. Finally, pep- 
tides  with  modifications  at  position  5  (P18  and  P19) 
blocked the antibody reaction with the same efficiency as 
the  natural  peptide.  In addition,  full inhibition  was seen 
with the acetylated and amidated tetrapeptide Ac-EEED- 
NH2 (not shown). These data are consistent with the possi- 
bility  that  the  epitope  recognized  by  anti--aSM-1  is  re- 
stricted  to  the  first four  amino  acids  of et-SM  actin  and 
includes the NH2-terminal acetyl moiety. 
The  same  specific  interactions  between  the  antibody 
and the peptides were also measured in an experiment in 
which the peptides, now conjugated to bovine serum albu- 
min as carrier, were used as targets. The different conju- 
gates were run on SDS-PAGE gels and transferred onto 
nitrocellulose  membranes.  Then  they  were  probed  with 
anti--aSM-1  as  primary  antibody  in  a  classical  Western 
blotting technique (Fig. 2). All peptides that were able to 
either completely or partially block a-SM actin antibody 
interaction in their free form were now specifically recog- 
nized  as  BSA-conjugates  in  Western  blotting  (Fig.  2). 
Those that did not display any inhibitory activity as free 
peptides were also not detected by immunoblotting. 
Effect of  Anti-aSM-I on a-SM Actin Polymerization 
In Vitro 
We  further  investigated whether  the  epitope  recognized 
by anti-~SM-1  is involved in a-SM actin polymerization, 
as it is known that a number of actin regulatory proteins 
can be chemically cross-linked via the NH2 terminus of ac- 
tin (Vandekerckhove, 1990).  This was done by measuring 
the extent of actin polymerization by a  sedimentation as- 
say and subsequent quantification of the protein present in 
the pellets and supernatants using SDS-PAGE (Chapon- 
Figure 1.  Blocking effect of NH2-terminal peptides on anti-aSM-1. 
Rat media total extracts  (3  ~g/lane)  were run on 5-15% SDS- 
PAGE and transferred on nitrocellulose  membrane. Nitrocellu- 
lose strips were incubated with anti-ctSM-1 hybridoma superna- 
tant (1:500) alone (control, lane 0) or mixed with the peptides (10 
Ixg/ml) listed in Table I (lane P1-P19). Only the a-SM NH2-termi- 
nal peptide (P1) and peptides with substitution  in position 5 (P18 
and P19) fully blocked the immunoreactivity of anti-aSM-1. 
Figure 2.  Detection of sequences  recognized  by anti--aSM-1 in 
denatured NH2-terminal peptides. Peptides listed in Table I were 
coupled to BSA, run on SDS-PAGE and transferred on nitrocel- 
lulose membrane. Anti--aSM-1 reacted with the a-SM NH2-ter- 
minal peptide (P1), a peptide modified in position 1 (Ala for Glu) 
(Pll), a peptide modified in position 4 (Glu for Asp) and with the 
two peptides having substitution  in position 5 (P18 and P19). 
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say of Kouyama and Mihashi (1981). 
Aortic SM actin  at 3.3  ~zM final  concentration was,  as 
expected, exclusively recovered in the supernatant  of low 
salt buffer (buffer G) (Fig. 3 A, condition 1). In physiolog- 
ical salt conditions (100 mM KC1, 2 mM MgC12, final con- 
centration), only 10-20% of SM actin was recovered in the 
pellet fraction (Fig. 3 A, condition 2). However, when ac- 
tin was mixed with  anti--aSM-1  (1.6  IxM final  concentra- 
tion)  in the  same  salt  conditions,  polymerization was in- 
duced, with more than 80% of the protein recovered in the 
pellet fraction together with the antibody (Fig. 3 A, condi- 
tion 3). The antibody did not induce a-SM actin polymer- 
ization in low salt buffer (Fig. 3 A, condition 4). As a con- 
trol it was shown that a-SK actin polymerized normally in 
physiological conditions and that there was no additional 
polymerization  when  anti--aSM-1  was  mixed  with  a-SK 
actin in a 1:2 antibody/actin molar ratio (Fig. 3 B). The an- 
tibody was  effective  even  substoichiometrically,  as  more 
than 60% of actin was recovered in the pellet fraction at a 
1:16 molar  ratio  (data  not  shown).  Control  experiments 
showed that an unrelated IgG had no effect on actin poly- 
merization (data not shown). 
We further measured the effect of the antibody on a-SM 
actin lower than 3.3 ~M, using a  1:2 antibody/actin molar 
ratio.  At a  0.8  t~M actin concentration, the antibody was 
still effective in inducing polymerization, as 50%  of actin 
was recovered in the pellet fraction, although in these con- 
ditions  actin  alone  was  hardly  polymerizable  (data  not 
shown). The polymerization effect of anti--aSM-1 through 
its  binding to AcEEED  sequence  was further proved by 
performing experiments in the presence of excess peptides 
(Fig. 4). Only the a-SM decapeptide (P1) and the epitopic 
tetrapeptide AcEEED inhibited the antibody effect on ac- 
tin assembly, leaving the antibody in the supernatant frac- 
Figure 4.  AcEEED containing peptides inhibit the polymeriza- 
tion effect of anti-aSM-1. ~-SM decapeptide P1 (10 t~g condition 
2;  2.5  Ixg  condition  3),  a-SK  decapeptide  P2  (condition  4), 
AcEEED (condition 5) or EEED (condition 6) were incubated 
with 12.5 Ixg of anti--aSM-1  for 10 min before adding actin and 
salt for the 30 min polymerization time as described in materials 
and methods section and in Fig. 3. The supernatants and pellets 
after  airfuge  centrifugation  were  analyzed on  Coomassie blue 
SDS-PAGE gel. Anti-aSM-1 with the bulk of actin were recov- 
ered in the pellet fraction in the control condition (no peptide 
added, condition 1) and when a-SK decapeptide P2 (condition 4) 
or the unacetylated tetrapeptide EEED were preincubated with 
the antibody. The a-SM decapeptide P1  (condition 2 and 3) as 
well as the acetylated tetrapeptide AcEEED (condition 5) inhib- 
ited the polymerization effect of anti-~SM-1, keeping the anti- 
body in the supernatant fraction. 
tion (conditions 2, 3, and 5). The ot-SK actin decapeptide 
(P2)  or the  unacetylated  tetrapeptide  EEED  did  not in- 
hibit the polymerizing effect of the antibody (conditions 4 
and 6), resulting in a recovery of anti--aSM-1 in the pellet 
together with the bulk of polymerized actin as in the posi- 
tive control (condition 1, antibody alone). 
Anti-aSM-1 Fab, containing a  single actin-binding site, 
showed the  same  effect as  the  complete  antibody mole- 
cule,  excluding  the  possibility  that  a-SM  actin  pelleting 
was  due  to  aggregation  by  anti--aSM-1.  This  point  was 
controlled at the electron microscopic level using negative 
staining of anti--aSM-l-induced actin filaments. As shown 
in Fig. 5, typical F-actin filaments were seen and no aggre- 
gated actin polymers were apparent. 
Figure 3.  Sedimentation assays. Effect of anti--aSM-1 on c~-SM ac- 
tin polymerization. (A) SM actin (3.3 p~M final) alone (1 and 2) or 
mixed with anti--aSM-1 (1.6 ixM final) (3 and 4) without (1 and 4) 
or with (2 and 3) salts (100 mM KC1 and 2 mM MgC12) was incu- 
bated for 30 min at room temperature and centrifuged at 30 PSI in 
a Beckman airfuge for 1 hour. Coomassie blue-stained  gels of pel- 
let (P) and supernatant (S) showed that SM actin is totally recov- 
ered in the supernatant when alone in buffer A  without salt  (1). 
When salt was added, only a small proportion of actin polymerized 
(2). The proportion of actin recovered in the pellet strongly in- 
creased when anti--aSM-1 was added to actin in polymerizing  con- 
ditions (3). The antibody was distributed  proportionally to actin in 
the two fractions (P and S). In depolymerizing conditions,  anti- 
aSM-1 had no influence  on actin polymerization (4). (B) Skeletal 
actin (3.3 tJ.M final) did not polymerize in the absence of salts (1) 
and polymerized in the presence of salts (2). Anti-c~SM-1 added to 
c~-skeletal actin in polymerizing conditions had no effect on poly- 
merization and was recovered in the supematant fraction (3). 
Figure 5.  Electron micrograph of negatively stained typical actin 
filaments induced by anti--aSM-1  in polymerizing buffer (same 
condition as in Fig. 3). Bar, 0.1 ixm. 
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Fig. 6 A  shows the rate of fluorescence increase after add- 
ing salts to a  solution containing 200 nM pyrene-labeled 
a-SM actin and 3.3  ~M unlabeled a-SK or ot-SM actin in 
the presence or absence of a  1:2 ratio of anti-aSM-1.  In 
the absence of the antibody, the fluorescence of the trace 
labeled a-SM actin did not increase during the 20 min of 
measurement. The slight decrease was due to photobleach- 
ing of the probe, which likely occurs because of the high il- 
lumination required  to detect the small concentration of 
labeled actin. In contrast, in the presence of the antibody, 
the fluorescence increased at a rate that was greater than 
the rate seen in the presence of 3.3  ~M oL-SK actin. The 
slowness  of the  fluorescence  change  at  very high  anti- 
ctSM-1 concentration is inconsistent with the antibody act- 
ing as an efficient nucleation  factor (Fig.  6 A). Fig.  6 B 
shows that the a-SM actin antibody affected the steady- 
state fluorescence levels as well as the rate of fluorescence 
change.  The fluorescence intensity  of a-SM actin in  the 
presence of saturating amounts of anti--aSM-1 were nearly 
identical  to  those  of ct-SK  actin,  indicating  that  under 
these conditions, the two actin isoforrns have similar criti- 
cal monomer concentrations (estimated to be 200 nM). In 
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Figure 6.  Pyrene actin assays. (A) Effect of anti--~SM-1 on kinet- 
ics of a-SM actin polymerization.  200 nM pyrene-labeled c~-SM 
actin  was mixed with 3.1  t~M unlabeled c~-SK actin  in  G-actin 
buffer (triangles) or  with  3.1  IxM unlabeled  a-SM  actin  with 
(closed circles) or without (open circles) anti--aSM-1 at a 1:2 anti- 
body/actin  ratio.  The  salt  concentration  was  raised  to  2  mM 
MgC12 and 100 mM KC1 by addition of a 10× concentrated stock, 
and the polymerization is shown as an increase in pyrene-fluores- 
cence. (B) Effect of anti-aSM-1 on the final extent of actin poly- 
merization.  The fluorescence,  proportional to the amount of po- 
lymerized actin, of samples such as those shown in Fig. 6 A but 
with  various concentrations  of unlabeled actins  was  measured 
12 h  after initiation  of polymerization.  Symbols have the same 
meaning as in Fig. 6 A. 
the  absence  of  antibody,  the  fluorescence  intensity  of 
a-SM actin was much lower, consistent with a critical con- 
centration of several IxM. The effect of the antibody on 
oL-SM actin fluorescence is due to polymerization of the 
actin rather than to a direct effect of the antibody on the 
fluorescence  of  the  labeled  actin  monomers,  because 
the antibody had a similar effect on oL-SM actin mixed with 
a  trace  of pyrene-labeled a-SK actin  (data  not  shown). 
Since the antibody does not bind to o~-SK actin, the fluo- 
rescence intensity of this actin can increase only if it incor- 
porates into a  complex with the a-SM actin that has the 
fluorescence properties of an actin filament. 
In  conclusion,  the  binding  of  anti--~SM-1  to  the 
AcEEED sequence of aortic actin likely induces a confor- 
mational change that converts monomeric actin into a po- 
lymerization competent form. The binding does not hinder 
the incorporation of the actin-antibody complex in the fil- 
aments. 
Action of Ac-EEED Microinjection on Stress Fiber 
Composition in Cultured SM Cells 
Our findings, that the critical monomer concentration of 
et-SM  actin  is  decreased  with  the  NH~ terminus-specific 
antibody,  raise  the  possibility  that  an  excess  of  the 
AcEEED peptide within the cell interferes with ct-SM ac- 
tin polymerization and incorporation into stress fibers. To 
test this possibility, both peptide P1 and epitopic tetrapep- 
tide  (AcEEED-NHz),  were  microinjected  into  cultured 
SM cells and the actin organization was subsequently ana- 
lyzed by double  immunostaining using  a  total actin-spe- 
cific polyclonal rabbit antibody and anti-aSM-1. 
Microinjection of PBS or nonblocking peptides diluted 
at 1 mg/ml into SM cells had no effect on actin organiza- 
tion;  double  staining  for total  actin  and  a-SM  actin  re- 
vealed the classical actin  stress fiber organization in un- 
treated as well as in buffer injected SM cells (Fig. 7, a and 
b).  On  the  other  hand,  a  striking  change  was  observed 
within 30 rain to 5 h  after microinjection of the peptide. 
Although the antibody recognizing all actin isoforms still 
decorated stress fibers in a normal pattern (Fig. 7 c), anti- 
aSM-1 failed to stain actin filaments or stained them only 
faintly (Fig. 7 d). In the same microscopic field, neighbor- 
ing noninjected cells showed typical stress fibers decorated 
by both antibodies (Fig. 7, c and d). Interestingly, the earli- 
est  changes  of  a-SM  actin  organization  were  only  ob- 
served about 30 min after injection. When fixed and per- 
meabilized cells were incubated with the active peptides 
before double staining, no effect on a-SM actin organiza- 
tion was noted.  These results  suggest that in vivo, a  dy- 
namic turnover of actin in stress fibers is necessary for the 
peptides to be active. 
Cells that were fixed 1-6 rain  after microinjection did 
not show an altered stress fiber organization revealed by 
either total actin or a-SM actin-specific antibody (Fig. 8, a 
and b). Within  1-6 min after microinjection, the biotiny- 
lated decapeptide appeared localized in a-SM actin con- 
taining stress fibers (Fig. 8, c and d) and disappeared later. 
When the biotinylated NH2-terminal peptide of a-skeletal 
actin was microinjected, it did not localize in stress fibers. 
These observations indicate that the failure of ot-SM actin 
staining 30 rain to 5 h after peptide injection is not simply 
Chaponnier et al. a-Smooth Muscle  Actin  NH  2 Terminus  and Polymerization  891 due  to  saturation  of  the  antibody  by  the  peptide  still 
present after permeabilization and fixation procedures. Our 
results  after  microinjection  of the  biotinylated  AcEEED 
peptide (Fig. 8, c and d), indicate that this peptide does not 
make the NH2 terminus of a-SM actin inaccessible for the 
antibody  (Fig.  8 d). It is also noteworthy that peptide  mi- 
croinjection  did  not  lead  to  complete  stress  fiber disrup- 
tion, as shown by the unaltered  total actin staining  (Fig. 7 
c), but that only the et-SM actin could not be detected any- 
more (Fig. 7 d). 
Discussion 
Anti-oLSM-1  was the  first monoclonal  antibody  described 
Figure  7.  Double  immuno- 
fluorescence staining for total 
actin (a and c) and for et-SM 
actin (b and d) of cultured rat 
aortic SM. 2 h after PBS mi- 
croinjection,  the  pattern  of 
stress fiber stainings for total 
actin (a) and for c~-SM actin 
(b)  are  similar  to  those  of 
noninjected  cells.  Although 
total actin (a) and a-SM actin 
(b) are mainly colocalized, a 
more  extended  staining  for 
total  actin  is  observed,  with 
longer  stress  fibers  and  dif- 
fuse  cytoplasmic staining.  In 
cells  microinjected  with  the 
NH2-terminal peptide P1 (ar- 
rows) the pattern of stress fi- 
ber staining for total actin is 
similar to that of noninjected 
neighboring  cells  (c)  but, 
stress fiber staining for c~-SM 
actin is practically abolished 
(d). Bar, 10 IxM. 
to be specific for a single actin isoform (Skalli et al., 1986b); 
it has proved a  reliable tool for the  study of vascular SM 
cell and myofibroblast phenotypic modulations  in physio- 
logical  and  pathological  processes  (Clowes  et  al.,  1988; 
Desmouli6re  and Gabbiani, 1994; Grinnell,  1994).  Our re- 
suits suggest that:  (a) AcEEED  is the  epitope recognized 
by anti-aSM-1,  (b) in vitro, the antibody and its Fab frag- 
ment increase a-SM actin polymerization  (conceivably by 
lowering  the  critical  monomer concentration),  (c)  in  cul- 
tured SM cells, the epitopic sequence plays a role in et-SM 
actin polymerization and stress fiber organization. 
Incubation of synthetic peptides with anti--aSM-1 showed 
that aspartic acid (D) in position 4 is essential for antibody 
recognition,  as it  represents  the  only  difference  between 
Figure  8.  Double  immuno- 
fluorescence  staining  for  to- 
tal actin (a) and for c~-SM ac- 
tin  (b),  for  the  biotinylated 
ct-SM actin NH2-terminal pep- 
tide  (c)  and  for  ct-SM  actin 
(d)  1-6  min  after  peptide 
microinjection.  The  patterns 
of stress fiber staining for to- 
tal actin (a) and for ct-SM ac- 
tin  (b)  in  P1  microinjected 
SM cells are similar to those 
of  non-injected  neighboring 
cells.  The  biotinylated  NH  2- 
terminal  decapeptide  as  re- 
vealed  by  FITC-streptavidin 
(c) is detected along stress fi- 
bers,  colocalized  with  a-SM 
actin staining (d). Bar, 10 IxM. 
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(AcEEET) or V-cytoplasmic (AcEEEI) actins. The acetyl 
blocking group also appears to be an integral part of the 
epitope. A  search in the  Swissprot  data bank  indicated 
that more than 300 mammalian proteins contain an EEED 
sequence not located at the NH2 terminus. Thus the speci- 
ficity of our antibody not only relies on the order and na- 
ture of the four amino acids but also on their relative posi- 
tion with respect to the blocking acetyl group. 
The sequence divergences among NH2-terminal ends of 
actin isoforms make this portion a  very likely candidate 
for specific interactions. Indeed a large number of actin- 
binding proteins (ABP) have been proposed to interact 
with the NHE-terminal domain (Vandekerckhove, 1990); 
as far as we know, none of them has been shown to specif- 
ically interact with a single isoform. Most of these studies 
were based on cross-linking or mutation techniques and 
surprisingly utilized mainly a-skeletal actin as test partner, 
not taking into account the well known NHE-terminal se- 
quence divergences among actin isoforms. Many ABP or 
their  fragments  containing  the  actin-binding  site  have 
been shown in vitro to have an actin polymerizing effect 
(Lewis et al., 1983; Vandekerckhove, 1990; Eto et al., 1991; 
Hartwig  and  Kwiatkowski,  1991;  Wang  et  al.,  1991; 
Friederich et al., 1992; Mannherz, 1992; Vancompernolle 
et al.,  1992; Vandekerckhove and Vancompernolle, 1992; 
Reisler, 1993). Most interactions between actin and ABP 
apparently involve salt bridges between the acidic residues 
of actin and basic domains of ABP (Vandekerckhove and 
Vancompernolle, 1992). However, it has been suggested 
that  these  interactions  with  NHE-terminal  residues  are 
charge  and  not  sequence  dependent  (Highsmith,  1990; 
Chase et al., 1991). The importance of ATP hydrolysis in 
the control of the actin monomer-polymer steady-state has 
been suggested in experiments where profilin was shown 
to promote actin filament assembly from the pool of actin- 
thymosin 134 complex (Pantaloni and Carlier, 1993). When 
compared to the  above mentioned reports, our findings 
deserve some  comments:  (a)  anti-aSM-1  binding  is  se- 
quence specific, and has a  polymerization effect only on 
a-SM actin; (b) the enhanced a-SM actin polymerization 
by anti-aSM-1 takes place only in physiological salt condi- 
tions. On the contrary, actin polymerization by the above 
mentioned ABP  and/or actin-binding  domains  was  pro- 
moted essentially in low salt condition (Eto et al.,  1991; 
Friederich et al., 1992; Vancompernolle et al., 1992); addi- 
tion of salt even reduced this effect, thus reinforcing the 
possibility of an electrostatic force interaction. 
We have no straightforward explanation about the actin 
polymerizing  activity  of  anti-aSM-1.  No  three-dimen- 
sional model of a-SM actin is presently available, but there 
is no reason to suspect that it is very different from the 
available a-skeletal (Kabsch et al., 1990) or [3-cytoplasmic 
actin models (Schutt et al., 1993). The NHE-terminal end in 
polymerized a-SM actin is probably exposed as indicated 
by  the  binding  of anti-aSM-1  by  immunofluorescence, 
similarly to what has been suggested for a-skeletal actin 
(Orlova et al., 1994). Our results suggest that anti-aSM-1 
binding  to  a-SM  actin  may  result  in  a  conformational 
change making it more competent for polymerization. If 
the COOH-terminal is in close vicinity to the NHE-termi- 
nal end of the molecule (Kabsch et al., 1990), the antibody 
binding could disrupt some electrostatic bonds and render 
a-SM actin more polymerizable by slightly changing the 
molecular conformation. Possibly our data cannot be in- 
terpreted solely in terms of critical concentration. We have 
recently obtained  evidence from  both  fluorescence mi- 
croscopy  of  rhodamine-phalloidin-labeled  F-actin  and 
from dynamic light scattering that a-SM actin even at high 
concentrations forms short filaments compared to those 
formed by a-SK actin under the same conditions (unpub- 
lished observations). It is conceivable that anti-aSM-1 in- 
creases the  average filament length  (as  we  observed by 
light  scattering)  and  this  effect alone  or  in  addition  to 
changes in the G/F actin ratio, contributes to the rise in 
fluorescence. 
We have further explored the role of the a-SM actin 
NH2-terminal peptide by microinjecting it in living cells. 
Disruption of stress fibers in nonmuscle cells has been ob- 
served after microinjection of several ABP (Fiachtbauer et 
al.,  1983;  Cooper et al.,  1987;  Sanger et al.,  1987,  1990; 
Franck et al.,  1990;  Huckriede et al.,  1990;  Pavalko and 
Burridge, 1991; Cao et al., 1992; Sanders et al., 1992; Ra- 
nucci et al., 1993). We have reported earlier that injection 
of two actin antibodies, both directed against the NH2-ter- 
minal end of actin but with different specificities (anti- 
aSM-1  and a  rabbit polyclonal antibody recognizing SM 
and cytoplasmic actin isoforms) affect in a different man- 
ner  stress  fiber  organization  in  SM  cells  (Skalli  et  al., 
1990).  Microinjection of the  general  antibody abolished 
most of the stress fiber staining by rhodamine-phalloidin, 
while  injection of anti--aSM-1  left practically intact  the 
rhodamine-phalloidin staining,  but displaced a-SM actin 
staining from stress fibers to a perinuclear, spotty distribu- 
tion (Skalli et al., 1990). This result suggests that microin- 
jected anti-aSM-1  interferes with the a-SM actin organi- 
zation in stress fibers, yet retaining it within the cytoplasm 
in  the  form  of  small  aggregates.  Our  present  results 
showed a selective localization of the peptide on stress fi- 
bers  shortly after microinjection and  a  practically com- 
plete  disappearance  of  anti-aSM-1  staining  starting  at 
~'-,30 min after the injection of the a-SM actin NHE-termi- 
nal  tetra-  or decapeptides.  Several mechanisms  may ac- 
count for this effect, e.g., interference with actin acetyla- 
tion or modification of stress fiber organization with loss 
of the epitope availability at the surface of the filaments. 
An  additional  attractive  possibility  is  that  the  peptide 
binds to a yet unknown protein that contains a sequence 
similar to that present in the antibody and helps the incor- 
poration of a-SM actin into stress fibers during the process 
of filament turnover in these cells. Further work is neces- 
sary to define the exact molecular mechanism of peptide 
stress fiber interactions. 
Cytoskeletal  proteins  are  highly  compartmentalized; 
this is probably true also for actin isoforms (Herman, 1993; 
Gimona et al.,  1994; North et al.,  1994). Although most 
work so far favors a coexpression of actin isoforms in sin- 
gle  microfilaments  (Otey et  al.,  1986), no  absolute  evi- 
dence of this possibility is presently available. Actin has 
been shown to exchange dynamically in cells like fibro- 
blasts from the G- to the F-pool and vice versa  (Wang, 
1984).  Various  experimental  approaches  (Kreis  et  al., 
1982;  Amato  and  Taylor,  1986;  Pavalko  and  Burridge, 
1991;  Theriot and Mitchison, 1991) have shown that the 
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life of actin in stress fibers was measured between 3.8 min 
using  photoactivation  of  caged  resorufin  actin  (Theriot 
and Mitchison,  1991)  and  10 min using fluorescence mi- 
croscopy after photobleaching (Kreis et al., 1982). Thinner 
stress  fibers  turn  over  more  rapidly  than  thicker  ones 
(Theriot  and  Mitchison,  1991).  Taking  into  account the 
rate of stress fiber turnover and the fact that any actin iso- 
form can participate in stress fiber formation, it is conceiv- 
able that filaments detected by the total actin antibody af- 
ter peptide  injection are newly formed by actin isoforms 
other than oL-SM actin. 
In conclusion our work has shown an hitherto unknown 
function of the NH2-terminal sequence AcEEED of et-SM 
actin.  Moreover, our microinjection experiments  suggest 
that the peptide AcEEED may be utilized for the study of 
the function of this ot-SM actin in cells such as SM cells, fi- 
broblasts, myofibroblasts, and myoepithelial cells in physi- 
ological and pathological situations during which ot-SM ac- 
tin  expression  is  modulated.  The  function  of  this  actin 
isoform has interested our and other laboratories for many 
years  (Desmouli~re  and  Gabbiani,  1994;  Grinnell,  1994) 
and up to now has been approached only indirectly. 
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